The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line TherapyGiovanni Fucà, Michele Del Vecchio, Lorenza Di Guardo et al.|Targeted Oncology|2021Cited by 61
Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.Francesca Corti, Lorenza Di Guardo, Giovanni Randon et al.|Journal of Clinical Oncology|2020Cited by 4